Pathogenetic relation between monoclonal gammopathies of undetermined significance and multiple myeloma
- PMID: 8520496
Pathogenetic relation between monoclonal gammopathies of undetermined significance and multiple myeloma
Abstract
Plasma cell atypia and cell proliferation changes which occur during the progression from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) are accompanied by critical changes in neoplastic plasma cells and marrow stromal cells. Key elements include paracrine secretion of interleukin 6 (IL-6) by marrow stromal cells resulting from interleukin 1 beta (IL-1 beta) secreted by myeloma cells. In addition, there are stable elevated levels of serum soluble IL-6 receptor (sIL-6R) in MM and MGUS. They are higher than levels seen in normals. Oncogenes such as c-myc and ras probably play a major role as do cell adhesion molecules and loss of apoptosis. Immune regulatory cells may also play a role. A key element yet to be clearly defined is delineating the role of circulating plasma cells and their precursors in spreading the disease.
Similar articles
-
MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells Costimulates pamidronate-activated gammadelta lymphocytes.Cancer Res. 2005 Aug 15;65(16):7502-8. doi: 10.1158/0008-5472.CAN-05-0731. Cancer Res. 2005. PMID: 16103105
-
Interaction between clonal plasma cells and the immune system in plasma cell dyscrasias.J Biol Regul Homeost Agents. 2004 Apr-Jun;18(2):161-5. J Biol Regul Homeost Agents. 2004. PMID: 15471221 Review.
-
A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.Cancer. 2003 May 15;97(10):2440-52. doi: 10.1002/cncr.11072. Cancer. 2003. PMID: 12733143 Review.
-
Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vbeta repertoire.Cancer. 2006 Mar 15;106(6):1296-305. doi: 10.1002/cncr.21746. Cancer. 2006. PMID: 16475149
-
New insights in the clinical biology of multiple myeloma.Semin Hematol. 1997 Jan;34(1 Suppl 1):23-8. Semin Hematol. 1997. PMID: 9122743 Review.
Cited by
-
Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component.Mayo Clin Proc. 2009 Feb;84(2):114-22. doi: 10.4065/84.2.114. Mayo Clin Proc. 2009. PMID: 19181644 Free PMC article. Clinical Trial.
-
Smoldering Multiple Myeloma Arising in Ulcerative Colitis.Chin Med J (Engl). 2018 Nov 5;131(21):2628-2629. doi: 10.4103/0366-6999.244114. Chin Med J (Engl). 2018. PMID: 30381604 Free PMC article. No abstract available.
-
Review article: multiple myeloma and inflammatory bowel disease.Dig Dis Sci. 2007 Sep;52(9):2022-8. doi: 10.1007/s10620-006-9165-6. Epub 2007 Apr 10. Dig Dis Sci. 2007. PMID: 17420948 Review.
-
Crohn's disease and smoldering multiple myeloma: a case report and literature review.Intest Res. 2017 Apr;15(2):249-254. doi: 10.5217/ir.2017.15.2.249. Epub 2017 Apr 27. Intest Res. 2017. PMID: 28522957 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical